High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma

Clinical Cancer Research

Volumn 17, Issue 15, 2011, Pages 5082-5092

  Schulte, Johannes H ^a   Bachmann, Hagen S ^a   Brockmeyer, Bent ^a   DePreter, Katleen ^b   Oberthur̈, André ^c   Ackermann, Sandra ^c   Kahlert, Yvonne ^c   Pajtler, Kristian ^a   Theissen, Jessica ^c   Westermann, Frank ^d   Vandesompele, Jo ^b   Speleman, Frank ^b   Berthold, Frank ^c   Eggert, Angelika ^a   Brors, Benedikt ^d   Hero, Barbara ^c   Schramm, Alexander ^a   Fischer, Matthias ^c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ADOLESCENT; ADULT; ALK GENE; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MOLECULAR CLONING; NEUROBLASTOMA; PHENOTYPE; POINT MUTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TRANSCRIPTOMICS; WILD TYPE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DNA COPY NUMBER VARIATIONS; GENE EXPRESSION; HUMANS; INFANT; INFANT, NEWBORN; MUTATION; NEUROBLASTOMA; PHENOTYPE; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 79961002472     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2809     Document Type: Article

References (37)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20. (Pubitemid 46935947)
2. Oberthuer A, Theissen J, Westermann F, Hero B, Fischer M. Molecular characterization and classification of neuroblastoma. Future Oncol 2009;5:625-39.
3. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16. (Pubitemid 37328872)
4. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971-4.
5. George RE, Sanda T, Hanna M, Fröhling S, Luther W, Zhang J, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455:975-8.
6. Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455:967-70.
7. Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-5.
8. Motegi A, Fujimoto J, Kotani M, Sakuraba H, Yamamoto T. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J Cell Sci 2004;117:3319-29. (Pubitemid 39139916)
9. Souttou B, Carvalho NB, Raulais D, Vigny M. Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J Biol Chem 2001;276:9526-31.
10. Webb TR, Slavish J, George RE, Look AT, Xue L, Jiang Q, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 2009;9:331-56.
11. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008;8:11-23.
12. McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008;68:3389-95.
13. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2010;16:4353-62.
14. Lamant L, Pulford K, Bischof D, Morris SW, Mason DY, Delsol G, et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 2000;156:1711-21. (Pubitemid 30646709)
15. Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 2005;167:213-22. (Pubitemid 40884782)
16. Ambros PF, Ambros IM. Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 2001;37:492-504. (Pubitemid 33101388)
17. ShimadaH, Chatten J, NewtonWA Jr., SachsN, HamoudiAB, Chiba T, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984;73:405-16. (Pubitemid 14055221)
18. De Preter K, Speleman F, Combaret V, Lunec J, Laureys G, Eussen BH, et al. Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. Mod Pathol 2002;15:159-66. (Pubitemid 34171326)
19. Pattyn F, Speleman F, De Paepe A, Vandesompele J. RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res 2003;31:122-3. (Pubitemid 36150349)
20. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 2007;8:R19.
21. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006;24:5070-8. (Pubitemid 46631411)
22. Fischer M, Skowron M, Berthold F. Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA. J Mol Diagn 2005;7:89-96. (Pubitemid 40310170)
23. Classen S, Zander T, Eggle D, Chemnitz JM, Brors B, Büchmann I, et al. Human resting CD4+ T cells are constitutively inhibited by TGF beta under steady-state conditions. J Immunol 2007;178:6931-40. (Pubitemid 46847419)
24. Fischer M, Bauer T, Oberthür A, Hero B, Theissen J, Ehrich M, et al. Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. Oncogene 2010;29:865-75.
25. Falcon S, Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics 2007;23:257-8. (Pubitemid 46189622)
26. Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 2010;28:3506-15.
27. Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 2008;416:153-9.
28. Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 2009;69:7338-46.
29. Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, Young LJ, et al. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res 2008;68:8286-94.
30. Oberthuer A, Kaderali L, Kahlert Y, Hero B, Westermann F, Berthold F, et al. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR. Clin Cancer Res 2008;14:6590-601.
31. Fischer M, Spitz R, Oberthur A, Westermann F, Berthold F. Risk estimation of neuroblastoma patients using molecular markers. Klin Padiatr 2008;220:137-46. (Pubitemid 351758156)
32. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009;27:1026-33.
33. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009;10:663-71.
34. Lo HS, Wang Z, Hu Y, Yang HH, Gere S, Buetow KH, et al. Allelic variation in gene expression is common in the human genome. Genome Res 2003;13:1855-62. (Pubitemid 36987191)
35. Yan H, Zhou W. Allelic variations in gene expression. Curr Opin Oncol 2004;16:39-43. (Pubitemid 38703470)
36. Zhang K, Li JB, Gao Y, Egli D, Xie B, Deng J, et al. Digital RNA allelotyping reveals tissue-specific and allele-specific gene expression in human. Nat Methods 2009;6:613-8.
37. de la Chapelle A. Genetic predisposition to human disease: allele-specific expression and low-penetrance regulatory loci. Oncogene 2009;28:3345-8.